ADCIRCA® 20mg (56 tablets)

Adcirca tablets contain the active ingredient tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor. Adcirca is indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability.

Adcirca tablets are available in strengths of 20 mg. The recommended starting dose is 40 mg once daily. Based on tolerability, the dose may be decreased to 20 mg or increased to 40 mg once daily.

Adcirca works by inhibiting PDE5 to promote blood vessel dilation. This improves exercise capacity in patients with PAH.

Common side effects may include headache, muscle pain, nausea, flushing, and limb pain. Adcirca should not be used in patients taking nitrates or guanylate cyclase stimulators due to risk of hypotension.

Adcirca can cause dizziness. Use caution when driving or operating machinery. Do not take Adcirca with grapefruit juice or avoid excessive drinking. Adhere to dosing instructions and do not split, crush, or chew tablets.

See full prescribing information for complete details on administration, dosage, warnings, precautions, and potential side effects. Discuss your medical history and medications with your doctor before starting Adcirca. Seek immediate medical care if chest pain, fainting, or sudden vision loss occurs.